From: Challenges in the design, planning and implementation of trials evaluating group interventions
 | Minimum number of sessions for ‘therapeutic dose’ (or per protocol population) | Median (range) sessions attended | Number of participants achieving ‘therapeutic dose’ (% of those receiving any intervention) | Number attending all planned sessions (% of those receiving any intervention) |
---|---|---|---|---|
LM [2] | 12/16 (75%) | 12 (1–16) | 71/123 (57.7%) | 5/123 (4.1%) |
PLINY [3] | 9/12 (75%) | 11 (2–12) | 9/21 (42.9%) | 10/21 (47.6%) |
REPOSE [4] | 4/5 (80%) | 5 (1–5) | 261/267 (97.8%) | 250/267 (93.6%) |
STEPWISE [5] | 2/7 a (28.6%) | Foundation: 3 (0–4) Booster: 2 (0–3) | 161/171 a (94.2%) | 47/171 a (27.5%) |
JtD [1] | 10/16 b (62.5%) | 1:1 sessions: 4 (1–4) Groups: 9 (0–12) | 168/217 b (77.4%) | 36/217 b (16.6%) |